Bio-Thera Solutions and STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi®? (golimumab). Under the agreement, Bio-Thera Solutions ("Bio-Thera") will maintain responsibility for development, manufacturing, and supply of BAT2506.

STADA ArzneimITTel AG ("STADA") will have exclusive rights to commercialize the product in the European Union (EU), the UK, Switzerland and selected other countries. Bio-Thera will receive an upfront payment of USD 10 million, as well as further development and commercial milestones of up to USD 147.5 million, subject to the fulfillment of certain conditions.olimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- a), a pro-inflammatory molecule. Binding of golimumab to TNF-a results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers.